See also this year's filing and all EDGAR filings for this company.
PDF Report 0000316253_2019_ENZO_BIOCHEM_INC.pdf
Logs
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 1.0900803321599422, 'aggregate_val': 115780000, 'exp_sum': 55395000, 'exp_to_value': {'LaborExpense': 0, 'CostOfGoodsAndServicesSold': 0, 'GeneralAndAdministrativeExpense': 44465000, 'GoodwillImpairmentLoss': 0, 'OperatingCostsAndExpenses': 0, 'DepreciationDepletionAndAmortization': 0, 'SellingAndMarketingExpense': 0, 'ResearchAndDevelopmentExpense': 3210000, 'remainder_Expenses': 7720000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000316253, ENZO BIOCHEM INC
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 9,338,000 |
| 1 | AssetsNonCurrent | 1,486,000 |
| 2 | AssetsCurrent | 83,200,000 |
| 3 | PropertyPlantAndEquipment | 7,636,000 |
| 4 | remainder_Assets | 0 |
| 5 | LongTermLiabilities | 353,000 |
| 6 | LiabilitiesCurrent | 20,186,000 |
| 7 | remainder_Liabilities | 0 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 0 |
| 10 | GeneralAndAdministrativeExpense | 44,465,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 0 |
| 15 | ResearchAndDevelopmentExpense | 3,210,000 |
| 16 | remainder_Expenses | 68,105,000 |
| 17 | remainder_Revenues | 104,713,000 |
| 18 | remainder_NetIncome | 746,000 |
| 19 | remainder_ComprehensiveNetIncome | 87,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 101,660,000 |
| 1 | Liabilities | 20,539,000 |
| 2 | Expenses | 115,780,000 |
| 3 | Revenues | 104,713,000 |
| 4 | StockholdersEquity | 81,121,000 |
| 5 | NetIncome | -10,321,000 |
| 6 | ComprehensiveNetIncome | -10,234,000 |
| 7 | BaseVar | 208,281,290 |
| 8 | EconomicCapitalRatio | 2.02 |
Edgar->Model Mapping
Feature Distribution
Change over Time
